Effects of serotonin on the cardiopulmonary circulatory system with and without 5-HT2-receptor blockade by ketanserin

J Breuer, R Meschig, HWM Breuer… - Journal of …, 1985 - journals.lww.com
Pulmonary embolism may cause pulmonary hypertension by mechanical obstruction, which
might be amplified by vasoconstriction induced by serotonin released from the emboli. The …

Serotonergic receptor subtypes and vascular reactivity

JM Van Nueten, JE Leysen, F De Clerck… - Journal of …, 1984 - journals.lww.com
Two distinct binding sites for serotonin have been identified in brain tissue and labeled 5-HT
1 and 5-HT 2 binding sites. The receptor mediating contractions of several types of vascular …

A comparative and long-term evaluation of ketanserin in the treatment of essential hypertension

T Hedner, B Persson, G Berglund - Journal of Cardiovascular …, 1985 - journals.lww.com
Ketanserin is a serotonin (S,) Mocker that reduces blood pressure (BP) in patients with
essential hypertension preferentially by a reduction of peripheral vascular resistance. Heart …

Recent advances in understanding serotonin regulation of cardiovascular function

F Côté, C Fligny, Y Fromes, J Mallet… - Trends in molecular …, 2004 - cell.com
Serotonin is an important neurohormonal factor that has been implicated in cardiovascular
function. It can regulate vascular tone, act directly on cardiomyocytes and stimulate …

Serotonin: a platelet hormone modulating cardiovascular disease

M Rieder, N Gauchel, C Bode… - Journal of thrombosis and …, 2021 - Springer
Cardiovascular diseases and depression are significant health burdens and increasing
evidence suggests a causal relationship between them. The incidence of depression among …

Serotonin and arterial vessels

PM Vanhoutte, RA Cohen… - Journal of Cardiovascular …, 1984 - journals.lww.com
The vasoconstrictor effects of serotonin can be explained by (a) activation of serotonergic
receptors on vascular smooth muscle,(b) activation, directly or indirectly, of postjunctional …

LY53857, a selective and potent serotonergic (5-HT2) receptor antagonist, does not lower blood pressure in the spontaneously hypertensive rat.

ML Cohen, RW Fuller, KD Kurz - Journal of Pharmacology and Experimental …, 1983 - ASPET
LY53857 was a potent antagonist of vascular contraction to serotonin, which is mediated by
serotonergic (5-HT2) receptors, with a dissociation constant in vitro of 5.4 X 10 (-11) M …

Central serotonergic mechanisms in cardiovascular regulation

J Minson, J Chalmers, G Drolet, V Kapoor… - … drugs and therapy, 1990 - Springer
This paper reviews the role of central serotonin-containing neurons in the control of blood
pressure. Central serotonin nerves have their cell bodies in the brainstem in a number of …

The pharmacology of specific, pure and potent serotonin 5-HT2 or S2-antagonists

PAJ Janssen - Biochemical Immunological Pharmacology, 1982 - Elsevier
Several members of the newly discovered ketanserin series of specific, pure and potent 5-
HT2-antagonists are essential tools for studying the role of serotonin (5-HT) in a wide variety …

[PDF][PDF] 5-Hydroxytryptamine (serotonin): receptor agonists and antagonists

E Sanders-Bush, SE Mayer - … of Therapeutics. 11th ed. New York …, 2006 - ndl.ethernet.edu.et
5-Hydroxytryptamine (5-HT, serotonin) is a regulator of smooth muscle in the cardiovascular
system and the gastrointestinal tract, an enhancer of platelet aggregation, and a …